Zhidong Xu, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Zhidong Xu, PhD

Assistant Adjunct Professor, Department of Surgery, UCSF

zxu@cc.ucsf.edu

Phone: (415) 502-0555 (voice)
Box 0875, UCSF, San Francisco, CA 94143-0875

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Cancer Genetics

Education

Shanghai Fisheries University, B.S., 1982, Marine Aquaculture
Western Illinois University, M.S., 1986, Biology/Cytogenetics
The University of Texas Medical Branch, Galveston, Ph.D., 1992, Molecular Mutagenesis


Professional Experience

  • 1986-1988
    Research Assistant, The University of Texas Medical Branch, Galveston, Texas
  • 1989-1991
    Co-principal Investigator, Laboratories for Genetic Services, Inc., Houston, Texas
  • 1986-1992
    Pre-doctoral Fellow, The University of Texas Medical Branch, Galveston, Texas
  • 1992-1993
    Postdoctoral Fellow, Human Genome mapping Center, UCSF
  • 1993-1998
    Post-graduate Molecular Biologist, Cardiovascular Research Institute, UCSF
  • 1998-2001
    Assistant Researcher, Department of Surgery, UCSF
  • 2001-present
    Assistant Adjunct Professor, Department of Surgery, UCSF

Honors & Awards

  • 1989
    Alexander Hollander Student Travel Award, Environmental Mutagen Society
  • 1987-1990
    Scholarships from American Lung Association/San Jacinto Area, Houston, Texas
  • 1992
    James E. Beall II Memorial Scholarship, The University of Texas Medical Branch
  • 1992
    The Doctor Edward Storrs Reynolds, Jr. Memorial Award, The University of Texas Medical Branch, Galveston, Texas
  • 1993
    Walter Travel Fund from American Lung Association, San Francisco

Selected Publications

  1. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. J Cell Mol Med. 2015 Oct; 19(10):2385-96.
    View on PubMed
  2. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget. 2015 Feb 28; 6(6):4357-68.
    View on PubMed
  3. Lung tumourigenesis in a conditional Cul4A transgenic mouse model. J Pathol. 2014 Jun; 233(2):113-23.
    View on PubMed
  4. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. Int J Oncol. 2013 Nov; 43(5):1517-22.
    View on PubMed
  5. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2. BMC Pharmacol Toxicol. 2013; 14:36.
    View on PubMed
  6. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer. 2013; 13:316.
    View on PubMed
  7. Inhibition of CK2a down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med. 2013 Jul; 17(7):854-62.
    View on PubMed
  8. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996.
    View on PubMed
  9. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3; 379(9818):823-32.
    View on PubMed
  10. Transgenic mice for cre-inducible overexpression of the Cul4A gene. Genesis. 2011 Mar; 49(3):134-41.
    View on PubMed
  11. Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med. 2011 Feb; 15(2):350-8.
    View on PubMed
  12. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol. 2011 Mar; 223(4):519-30.
    View on PubMed
  13. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer. PLoS One. 2010; 5(7):e11418.
    View on PubMed
  14. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther. 2010 Apr; 9(4):1058-69.
    View on PubMed
  15. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer. 2009; 9:135.
    View on PubMed
  16. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008 Jul; 30(7):946-63.
    View on PubMed
  17. Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription. Mol Cancer Ther. 2008 Jun; 7(6):1633-8.
    View on PubMed
  18. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71.
    View on PubMed
  19. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci. 2008 Jan; 99(1):46-53.
    View on PubMed
  20. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer. 2007 Sep 15; 121(6):1175-81.
    View on PubMed

Go to UCSF Profiles, powered by CTSI